Neuren Pharmaceuticals Limited (NEU) Fair Value & Analysis
Healthcare · AU · Market cap A$1.7B
Fair value as of: Jun 24, 2026
From 23 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from A$11.19 to A$3.00 (−73.2%) since Jun 23, 2026. Share price −11.8% over the past month.
Price vs Fair Value (12 months)
12‑month range A$11.45 – A$22.30 · fair‑value band A$2.26 – A$3.74 · the A$12.38 price screens above the A$3.00 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Neuren Pharmaceuticals Limited (NEU) currently trades at A$12.38, while our model-based Fair Value estimate is A$3.00 — implying the stock looks roughly 75.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Neuren Pharmaceuticals Limited generated revenue of A$64.6M at a net margin of 47.1%. Revenue declined 80.9% year over year. It earns a return on equity of 8.7%. The balance sheet holds a net cash position of A$4.2M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Neuren Pharmaceuticals Limited reported revenue of A$64.6M in FY2025 versus A$3.2M in FY2021, a compound +112.0%/yr. Reported net income was A$30.4M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$607.20 | R$74.60 | -88% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Neuren Pharmaceuticals Limited (NEU) undervalued?
What is the fair value of NEU?
What is the quality score of NEU?
What is the revenue of Neuren Pharmaceuticals Limited (NEU)?
What is the net profit margin of NEU?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.